
IMBRUVICA® for CLL/SLL
IMBRUVICA® (ibrutinib) Has Helped Many Adults With CLL/SLL Live Longer1
- In one clinical trial, of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy1
- In another clinical trial of 391 previously treated people with CLL or SLL, people who took IMBRUVICA® had a 57% lower risk of death compared to those taking an immunotherapy (ofatumumab). With a median follow-up of approximately 9 months, 8% of IMBRUVICA® patients died compared to 17% taking an immunotherapy1,2
IMBRUVICA® lowered the risk of disease progression or death vs approved therapies1-3
- In one clinical trial of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had an 84% lower risk of disease progression or death compared to those taking a chemotherapy. With a median follow-up of 18 months, 11% of IMBRUVICA® patients had disease progression or died compared to 48% taking a chemotherapy1,3
- In another clinical trial of 391 previously treated people with CLL or SLL, people who took IMBRUVICA® had a 78% lower risk of disease progression or death compared to those taking an immunotherapy. With a median follow-up of approximately 9 months, 18% of IMBRUVICA® patients had disease progression or died compared to 57% taking an immunotherapy1,2
IMBRUVICA® will not work for every patient. Individual results may vary.
What you should know about the side effects of IMBRUVICA® (ibrutinib)1
IMBRUVICA® may cause serious side effects, including:
- Bleeding problems (hemorrhage)
- Infections
- Heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter), heart failure and death
- High blood pressure (hypertension)
- Decrease in blood cell counts
- Second primary cancers
- Tumor lysis syndrome (TLS)*
*TLS is a disorder caused by the breakdown products of cancer cells, which can lead to kidney failure and other abnormalities.
The most common side effects in the clinical trials were:
- Low platelet count
- Diarrhea
- Tiredness
- Muscle and bone pain
- Low white blood cell count
- Rash
- Low red blood cell count
- Bruising
- Nausea
In the clinical trials, approximately 4%-10% of CLL or SLL patients stopped
taking IMBRUVICA® because of side effects.
This is not a complete list of side effects. Others may occur. Tell your doctor if you think you are experiencing side effects.

Have questions about IMBRUVICA®?
From cost and coverage options to Ambassador support - we're here to help.
Our way: real journeys with IMBRUVICA®
Hear people share stories about their diagnosis of CLL/SLL—and the difference IMBRUVICA® has made
References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. 2. Byrd JC, Brown JR, O’Brien S, et al; for the RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223. 3. Burger JA, Tedeschi A, Barr PM, et al; for the RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.